Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 152.50 GBp
Change Today -0.25 / -0.16%
Volume 46.3K
As of 11:35 AM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

advanced medical solutions (AMS) Snapshot

152.75 GBp
Previous Close
152.75 GBp
Day High
152.75 GBp
Day Low
151.75 GBp
52 Week High
05/21/15 - 161.00 GBp
52 Week Low
11/6/14 - 111.00 GBp
Market Cap
Average Volume 10 Days
0.07 GBp
Shares Outstanding
0.81 GBp
Dividend Yield

Related News

No related news articles were found.

advanced medical solutions (AMS) Related Businessweek News

No Related Businessweek News Found

advanced medical solutions (AMS) Details

Advanced Medical Solutions Group plc, together with its subsidiaries, designs, develops, manufactures, and distributes natural and synthetic polymers for use in advanced woundcare products and surgical dressings worldwide. The company operates through Branded Direct, Branded Distributed, Original Equipment Manufacturer, and Bulk Materials segments. It also offers medical adhesives and sutures for closing and sealing tissues; haemostats; and bulk materials to medical device partners and convertors. The company offers its advanced woundcare products under the ActivHeal brand name; medical adhesives under the LiquiBand brand; and sutures and haemostats under the RESORBA brand name. It serves healthcare companies and distributors, as well as hospital and dental markets, and NHS. The company was founded in 1991 and is headquartered in Winsford, the United Kingdom.

470 Employees
Last Reported Date: 09/9/15
Founded in 1991

advanced medical solutions (AMS) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 386.0K GBP
Group Finance Director, Company Secretary and...
Total Annual Compensation: 256.0K GBP
Compensation as of Fiscal Year 2014.

advanced medical solutions (AMS) Key Developments

Advanced Medical Solutions Group plc Declares Interim Dividend; Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015

The Board of Advanced Medical Solutions Group plc intends to pay an interim dividend of 0.25 pence per share against 0.22 pence per share a year ago, an increase of 13.6%, on 30 October 2015 to shareholders on the register at the close of business on 2 October 2015. The company reported unaudited consolidated earnings results for the six months ended June 30, 2015. For the period, the company reported revenue from continuing operations of GBP 32,713,000 against GBP 29,440,000 a year ago. Profit from operations was GBP 8,046,000 against GBP 7,027,000 a year ago. Profit before taxation was GBP 8,015,000 against GBP 7,054,000 a year ago. Profit for the period attributable to equity holders of the parent was GBP 6,661,000 against GBP 5,964,000 a year ago. Diluted earnings per share were 3.15 pence against 2.82 pence a year ago. Adjusted diluted earnings per share were 3.23 pence against 2.92 pence a year ago. Net cash inflow from operating activities was GBP 7,256,000 against GBP 6,232,000 a year ago. Purchases of property, plant and equipment were GBP 960,000 against GBP 553,000 a year ago. Adjusted profit before tax was GBP 8.2 million against GBP 7.3 million a year ago.

Advanced Medical Solutions Seeks Acquisitions

Advanced Medical Solutions Group plc (AIM:AMS) is seeking acquisitions. Advanced announced that it continues to evaluate and consider potential acquisitions.

Advanced Medical Solutions Group Plc Receives CE Approval to Market its Polyhexamethylene Biguanide

Advanced Medical Solutions Group plc (AMS.L) announced that it has received CE approval to market its Polyhexamethylene Biguanide (PHMB) non adhesive antimicrobial foam dressing in Europe. PHMB has been shown to be effective against several bacteria including, amongst others, Staphylococcus Aureus including the methicillin resistant type, and Escherichia Coli. This antimicrobial foam wound dressing may be used throughout the healing process on moderate to heavily exuding chronic and acute wounds that are infected or are at risk of infection and may be used on pressure ulcers, leg and foot ulcers, diabetic ulcers and surgical wounds. AMS expects to launch this product through its OEM partners in 2015, as well as including it in its ActivHeal range of woundcare dressings for the NHS.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMS:LN 152.50 GBp -0.25

AMS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMS.
View Industry Companies

Industry Analysis


Industry Average

Valuation AMS Industry Range
Price/Earnings 23.3x
Price/Sales 4.7x
Price/Book 3.3x
Price/Cash Flow 23.0x
TEV/Sales 4.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVANCED MEDICAL SOLUTIONS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at